Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 3, 2015
The FDA’s decision that consumers need not go through a licensed practitioner to have direct access to personal genetic information was a crack-in-the-dam moment for the direct-to-consumer world of precision medicine. So how is the medical industry adjusting to this new reality? What is the new role for healthcare providers? And how do we, as an industry, provide the right information to patients so they know what to do with their genetic information?
Listen to the audience Q&A of the session, which was moderated by David Kroll and included Alberto Gutierrez, Ph.D., Director - Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health; Glenn S. Gerhard, Professor and Chair of the Department of Medical Genetics and Molecular Biochemistry , Temple University School of Medicine; and Susan Hertzberg, President and CEO, Boston Heart Diagnostics.